CD8A and non-small cell lung carcinoma: Single-cell RNA sequencing (scRNA-seq) of NSCLC samples, both before and after anti-PD-1 treatment, showed that patients who respond to treatment have a higher number of CD8+ T cells, suggesting their potential as predictors of anti-PD-1 therapy success.